Welcome to our dedicated page for Hillstream BioPharma news (Ticker: hils), a resource for investors and traders seeking the latest updates and insights on Hillstream BioPharma stock.
Hillstream BioPharma, Inc. (NASDAQ: HILS) is a biotechnology innovator advancing novel therapies for drug-resistant cancers and chronic conditions. This page provides a comprehensive resource for verified news on clinical developments, strategic partnerships, and regulatory milestones.
Investors and industry observers will find updates on Hillstream’s proprietary platforms, including Quatramer™ for targeted drug delivery and Quatrabody™ conjugates designed to improve immuno-oncology outcomes. Track progress on lead candidates like HSB-1940 (targeting PD-1) and HSB-3215, a bi-specific antibody addressing HER2/HER3-driven cancers.
Stay informed about collaborations with research institutions such as the Applied Biomedical Science Institute and partners like Minotaur Therapeutics, alongside pipeline expansions into chronic pruritis treatments via the AV104 asset. This page consolidates press releases on trial results, licensing agreements, and therapeutic advancements.
Bookmark this page for timely updates on Hillstream’s progress in transforming oncology care and addressing unmet medical needs through cutting-edge biotechnologies.
FAQ
What is the market cap of Hillstream BioPharma (hils)?
